Hamada S. Abulkhair

Associate Prof.

CONTACT

PHONE:
+201090468540

WEBSITES:
Google Scholar
Scopus
ResearchGate
ORCID Profile

EMAIL:
hamadaorganic@azhar.edu.eg

habouelkhier@zewailcity.edu.eg

habulkhair@horus.edu.eg

I received my B.S. degree in Pharmaceutical Sciences from the *University of Al-Azhar* in 1997. Then, I also received my M.S. (2007) and Ph.D. (2010) degrees from the same University, both in *Pharmaceutical Organic Chemistry*. In 2012 and for two years, I joined the College of Pharmacy at *Omar Al-Mukhtar University*, Libya as an adjunct Lecturer of Pharmaceutical Organic Chemistry. Also, I went to *Zewail City of Science and Technology* where I was promoted to Associate Professor in 2017. Furthermore, I worked as adjunct associate Professor at Faculties of Pharmacy in both *Menoufia University* and *Badr University in Cairo*. My principal research efforts include the development of small molecule inhibitors of adenosine receptor (A2B), VEGFR-2, and histone acetyl transferase (PCAF) for the treatment of cancer. This research combines tools from organic synthesis, structural biology and molecular modeling. My published articles include Seventeen articles in moderate to high-ranked peer-reviewed journals, including *European Journal of Medicinal Chemistry, Bioorganic Chemistry, Scientific Reports, RSC Advances, Archiv der Pharmazie, Molecules, New Journal of Chemistry, Journal of Biomolecular Structure & Dynamics, Bioorganic & Medicinal Chemistry, Heliyon, Molecular Diversity, Journal of heterocyclic Chemistry,* Future Medicinal Chemistry, *and Pharmaceuticals*. I'm currently serving as an adjunct Associate Professor at the Department of *Pharmaceutical Chemistry* at *Horus University* in Egypt since 2018.

Hamada S. Abulkhair

Thursday, October 5, 2023

Curriculum Vitae

Personal Data:

- Name: Hamada Elsayed Abulkhair
- Birth date: 04 - 09 - 1974
- Address: 27 Ramsis Extension 2, Nasr City 11884, Cairo, Egypt.
- Phone: +201090468540
- E-Mail: hamadaorganic@azhar.edu.eg

Present Profession:

- Associate Professor of Pharmaceutical Organic Chemistry at Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
- Associate Professor of Pharmaceutical Organic Chemistry at Faculty of Pharmacy, Horus University in Egypt, International Costal Road, Egypt.

Qualifications:

- B.Sc. Pharmaceutical Sciences, Faculty of Pharmacy, Al-Azhar University 1997.
- M.Sc. Pharmaceutical Sciences, (Pharmaceutical Organic Chemistry), Faculty of Pharmacy, Al-Azhar University 2007.
- Ph.D. Pharmaceutical Sciences, (Pharmaceutical Organic Chemistry), Faculty of Pharmacy, Al-Azhar University 2010.

Academic Career:

- Laboratory demonstrator of Pharmaceutical Organic Chemistry at the, Faculty of Pharmacy, Al-Azhar University, July 2000 until December 2006.
- Assistant Lecturer in Pharmaceutical Organic Chemistry department, Faculty of Pharmacy, Al-Azhar University, January 2007 until March 2010.
- Lecturer of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, March 2010 until May 2012.
- Lecturer of Organic Chemistry, Faculty of Pharmacy, Omar Al-Mukhtar University, May 2012 until July 2014.
- Lecturer of Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, July -2014 until 07-2017.

- Associate Professor of Pharmaceutical Organic Chemistry at Faculty of Pharmacy, Al-Azhar University, 07-2017 to the present.
- Part-time Associate Professor of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, and Pharmaceutical industries, Badr University in Cairo, September 2015 until January 2016.
- Part-time Associate Professor of Pharmaceutical Organic Chemistry, Zewail City of Sciences and Technology, Sheikh Zayed District, 6th of October City, Giza, Egypt, January 2017 until June 2018.
- Part-time Associate Professor of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Menoufia University, January 2018 until June 2019.
- Full-time Associate Professor of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Horus University in Egypt, September 2018 until now.

Course Work:

1. Introduction to Pharmaceutical Organic Chemistry, Stereochemistry, (Al-Azhar University, Cairo, Egypt), Academic Year 2010.
2. Aliphatic & aromatic compounds, (Al-Azhar University, Cairo, Egypt), Academic Year 2011.
3. Heterocyclic and Polynuclear compounds, (Al-Azhar University, Cairo, Egypt), Academic Year 2011.
4. Carbohydrates, (Al-Azhar University, Cairo, Egypt), Academic Year 2011.
5. Spectroscopy, (Al-Azhar University, Cairo, Egypt), Academic Year 2012.
6. General Chemistry, Introduction to Organic Chemistry and aromatic organic compounds, (Omar Al-Mukhtar University, Derna, Libya), Academic Years 2012 and 2013.
7. Spectroscopic Methods for Identification of Organic Compounds, (Omar Al-Mukhtar University, Derna, Libya), Academic Years 2012 and 2013.
8. Chemistry of aromatic compounds, Faculty of Pharmacy, and Pharmaceutical industries, Badr University in Cairo Academic Year 2015.
9. General Chemistry and Organic Chemistry, Zewail City of Science and Technology, 6th of October City, Egypt, Academic Year 2016, 2017.
10. Basic Concepts of Organic Chemistry, Chemistry of Aliphatic and Aromatic compounds, & Polymers and Carbohydrates, (Menoufia University, Shebin El-Koum, Egypt), Academic Years 2017-2019.

11. Basic Concepts of Organic Chemistry, Chemistry of Aliphatic and Aromatic compounds, & Heterocyclic Chemistry, (Horus University, New Damietta, Egypt), Academic Years 2018-2020.

Scientific and Career Activities:

1. Active member in the Egyptian Pharmacists Syndicate since 1997.
2. Member of the Egyptian Pharmaceutical Association since 1997.
3. Member in the Academic staff club, Al-Azhar University from 2000.
4. Active member in the Educational Services Association in Faculty of Pharmacy, Al-Azhar University since 2010.
5. Active member in the Educational Services Association in Faculty of Pharmacy, Omar Al-Mukhtar University since 2012.

Experiences:

1. Teaching practical Organic Chemistry in the Faculty of Pharmacy, Al-Azhar University, from 2000 to 2007.
2. Assistant lecturer in Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, from 2007 to 2010.
3. Experience in Organic synthesis and formulation.
4. Lecturer in Organic Chemistry for preparatory & first- and second-year pharmacy, Faculty of Pharmacy, Al-Azhar University, 2010.
5. Lecturer in Organic Chemistry for preparatory & first- and second-year pharmacy, Faculty of Pharmacy, Omar Al-Mukhtar University, 2012.

Conference Attendance:

1. 3rd International Conference of Pharmaceutical Sciences (MU-PHARM 2022), Faculty of Pharmacy, Mansoura University/El-Ein- El-Sokhna, 30-08-2022 – 02-09-2022

2. 2nd International Conference of Pharmaceutical Sciences (MU-PHARM 2019), Faculty of Pharmacy, Mansoura University/El-Ein- El-Sokhna, 09-04-2019 – 12-04-2019

3. 1st international conference of Faculty of Pharmacy, Menofia University "Drug Development: From Benchside To Bedside", August 11th - 12th , 2018

4. Arab Diabetes Forum 2017 Venue, Intercontinental City Stars Hotel, September 20th - 22nd, 2017.

5. Al-Azhar 5th International Conference of Pharmaceutical Sciences and Drug Industries (AICPD) Hurghada, Egypt September 13th – 15th 2017.
6. 2016 American Association of Pharmaceutical Scientists annual meeting and Exposition, Colorado Convention Center, Denver, United States of America, November 13th-17th 2016.
7. 2nd Scientific Conference of Faculty of Pharmacy, Cairo University, Egypt, April, 26th, 2010.
8. 11th International chemistry and exhibitions conference in Africa, Luxor, Egypt, November 20th – 23th 2010.
9. 13th Conference for the Pan Arabian Conference for the Colleges of Pharmacy of the Assembly of Arab Universities (AARU). 6th October City, Egypt, May 10th – 13th 2010

Published Articles:

1. Novel fused imidazotriazines acting as promising top. II inhibitors and apoptotic inducers with greater selectivity against head and neck tumors: Design, synthesis, and biological assessments, Ahmed A. Al-Karmalawy, Mahmoud Rashed, Marwa Sharaky, ***Hamada S. Abulkhair***, Mohamed M. Hammouda, Haytham O. Tawfik, Moataz A. Shaldam, *European Journal of Medicinal Chemistry*, 2023, 115661, https://doi.org/10.1016/j.ejmech.2023.115661
2. Aminopyridone-linked Benzimidazoles: A Fragment-based Drug Design for the Development of CDK-9 Inhibitors, Ebtehal M. Husseiny, ***Hamada S. Abulkhair***, Sanadelaslam SA El-Hddadd, Nada Osamae, Mona S. El-Zoghbi, *Future Medicinal Chemistry*, 2023, https://doi.org/10.4155/fmc-2023-0139
3. Molecular overlay-guided design of new CDK2 inhibitor thiazepinopurines: Synthesis, anticancer, and mechanistic investigations, Ebtehal M. Husseiny, ***Hamada S. Abulkhair***, Asmaa Saleh, Najla Altwaijry, Riham A. Zidan, Fatma G. Abdulrahman, *Bioorganic Chemistry*, 2023, https://doi.org/10.1016/j.bioorg.2023.106789
4. Design and synthesis of novel uracil-linked Schiff bases as dual histone deacetylase type II/topoisomerase type I inhibitors with apoptotic potential, Samar El-Kalyoubi, Samar S Elbaramawi, Ahmed G Eissa, Essam Al-Ageeli, Yahya Hasan Hobani, Aya Ali El-Sharkawy, Hossam Taha Mohamed, Ahmed A Al-

Karmalawy, ***Hamada S. Abulkhair***, *Future Medicinal Chemistry*, 2023, https://doi.org/10.4155/fmc-2023-0112

5. Geigeria alata-a potential source for anti-Alzheimer's constituents: In vitro and computational investigations, Sabrin Ibrahim, Wadah Osman, Mohamed A. Maaz, Amna Ali, Eltayeb Fadul, Ahmed H. Arbab, Mosab Yahya Al-Nour, Ahmed Ashour, Asmaa E. Sherif, ***Hamada S. Abulkhair***, Kholoud F. Ghazawi, Gamal A. Mohamed, Mona S. Mohamed, *Indonesian Journal of Pharmacy*, 2023, https://doi.org/10.22146/ijp.7967
6. Exploring the dual effect of novel 1, 4-diarylpyranopyrazoles as antiviral and anti-inflammatory for the management of SARS-CoV-2 and associated inflammatory symptoms, Azizah M Malebari, Hany EA Ahmed, Saleh K Ihmaid, Abdelsattar M Omar, Yosra A Muhammad, Sultan S Althagfan, Naif Aljuhani, Abdel-Aziz AA El-Sayed, Ahmed H Halawa, Heba M El-Tahir, Safaa A Turkistani, Mohammed Almaghrabi, Ahmed KB Aljohani, Ahmed M El-Agrody, ***Hamada S. Abulkhair***, *Bioorganic Chemistry*, 2023, https://doi.org/10.1016/j.bioorg.2022.106255
7. Exploring the cytotoxic effect and CDK-9 inhibition potential of novel sulfaguanidine-based azopyrazolidine-3, 5-diones and 3, 5-diaminoazopyrazoles, Ebtehal M Husseiny, ***Hamada S. Abulkhair***, Nehad M El-Dydamony, Kurls E Answer, *Bioorganic Chemistry*, 2023, https://doi.org/10.1016/j.bioorg.2023.106397
8. The anticancer and EGFR-TK/CDK-9 dual inhibitory potentials of new synthetic pyranopyrazole and pyrazolone derivatives: X-ray crystallography, *in vitro*, and *in silico* mechanistic investigations, Arafa Musa, Saleh K Ihmaid, David L Hughes, Musa A Said, ***Hamada S. Abulkhair***, Ahmed H El-Ghorab, Mohamed A Abdelgawad, Khaled Shalaby, Mohamed E Shaker, Khalid Saad Alharbi, Nasser Hadal Alotaibi, Deborah L Kays, Laurence J Taylor, Della Grace Thomas Parambi, Sami I Alzarea, Ahmed A Al-Karmalawy, Hany EA Ahmed, Ahmed M El-Agrody, *Journal of Biomolecular Structure and Dynamics,* 2023, https://doi.org/10.1080/07391102.2023.2167000
9. A novel class of phenylpyrazolone-sulphonamides rigid synthetic anticancer molecules selectively inhibit the isoform IX of carbonic anhydrases guided by molecular docking and orbital analyses, Maan T Khayat, Hany EA Ahmed, Abdelsattar M Omar, Yosra A Muhammad, Khadijah A Mohammad, Azizah M Malebari, Ahdab N Khayyat, Ahmed H Halawa, ***Hamada S. Abulkhair***, Ahmed A Al-

Karmalawy, Mohammed Almaghrabi, Majed Alharbi, Anfal S Aljahdali, Ahmed M El-Agrody, *Journal of Biomolecular Structure and Dynamics,* 2023, https://doi.org/10.1080/07391102.2023.2188957

10. Phenylpyrazolone-1, 2, 3-triazole Hybrids as Potent Antiviral Agents with Promising SARS-CoV-2 Main Protease Inhibition Potential, Arafa Musa, ***Hamada S. Abulkhair***, Ateyatallah Aljuhani, Nadjet Rezki, Mohamed A Abdelgawad, Khaled Shalaby, Ahmed H El-Ghorab, Mohamed R Aouad, *Pharmaceuticals,* 2023, https://doi.org/10.3390/ph16030463
11. *In vitro* and computational investigations of novel synthetic carboxamide-linked pyridopyrrolopyrimidines with potent activity as SARS-CoV-2-M^{Pro} inhibitors, Ateyatallah Aljuhani, Hany E. A. Ahmed, Saleh K. Ihmaid, Abdelsattar M. Omar, Sultan S. Althagfan, Yaser M. Alahmadi, Iqrar Ahmad, Harun Patel, Sahar Ahmed, Mohannad A. Almikhlafi, Ahmed M. El-Agrody, Mohamed F. Zayed, Safaa Abdulrahman Turkistani, Shorouk H. Abulkhair, Mohammed Almaghrabi, Samir A. Salam, Ahmed A. Al-Karmalawy & ***Hamada S. Abulkhair***, *RSC Advances,* 2022,**12**, 26895-26907. https://doi.org/10.1039/D2RA04015H
12. Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: *in vitro* and *in silico* drug repurposing studies, Omnia Kutkat, Yassmin Moatasim, Ahmed A. Al-Karmalawy, ***Hamada S. Abulkhair***, Mokhtar R. Gomaa, Ahmed N. El-Taweel, Noura M. Abo Shama, Mohamed GabAllah, Dina B. Mahmoud, Ghazi Kayali, Mohamed A. Ali, Ahmed Kandeil & Ahmed Mostafa, *Scientific Reports*, 2022, https://www.nature.com/articles/s41598-022-17082-6
13. The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia, Esraa M. Othman, Eman A. Fayed, Ebtehal M.Husseiny, ***Hamada S. Abulkhair***, *Bioorganic Chemistry*, 2022, https://doi.org/10.1016/j.bioorg.2022.105968
14. New quinoxalin-2(1H)-one-derived VEGFR-2 inhibitors: Design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies, Khaled El-Adl, Helmy M. Sakr, Reda G. Yousef, Ahmed B. M. Mehany, ***Hamada S. Abulkhair***, Ibrahim H. Eissa, *Archiv der Pharmazie*, 2022, 202200048, https://doi.org/10.1002/ardp.202200048
15. Apoptosis induction, PARP-1 inhibition, and cell cycle analysis of leukemia cancer cells treated with novel synthetic 1,2,3-triazole-chalcone conjugates, Esraa M.

Othman, Eman A. Fayed, Ebtehal M. Husseiny, ***Hamada S. Abulkhair***, *Bioorganic Chemistry*, 2022, https://doi.org/10.1016/j.bioorg.2022.105762

16. Rationale design, synthesis, cytotoxicity evaluation, and in silico mechanistic studies of novel 1,2,3-triazoles with potential anticancer activity, Esraa M. Othman, Eman A. Fayed, Ebtehal M. Husseiny, ***Hamada S. Abulkhair***, *New Journal of Chemistry*, 2022, https://doi.org/10.1039/D2NJ02061K
17. Synthesis, structural characterization, DFT calculations, molecular docking, and molecular dynamics simulations of a novel ferrocene derivative to unravel its potential antitumor activity, Mohamed M. Hammoud, Muhammad Khattab, Marwa Abdel-Motaal, Johan Van der Eycken, Radwan Alnajjar, ***Hamada S. Abulkhair*** & Ahmed Ali Al-Karmalawy, *Journal of Biomolecular Structure & Dynamics*, 2022, https://www.tandfonline.com/doi/full/10.1080/07391102.2022.2082533
18. Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors, Khaled El-Adl, Mohamed K. Ibrahim, Fathalla Khedr, ***Hamada S. Abulkhair***, Ibrahim H. Eissa, *Archiv der Pharmazie*, 2022, 2100278, https://doi.org/10.1002/ardp.202100278
19. From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity, Mohamed H. El-Shershaby, Adel Ghiaty, Ashraf H. Bayoumi, Ahmed A.Al-Karmalawy, Ebtehal M.Husseiny, Mona S. El-Zoghbi, ***Hamada S. Abulkhair***, *Bioorganic & Medicinal Chemistry,* 2021, https://doi.org/10.1016/j.bmc.2021.116266
20. 1,2,4-Triazolo[4,3-c]quinazolines: a bioisosterism-guided approach towards the development of novel PCAF inhibitors with potential anticancer activity, Mohamed H. El-Shershaby, Adel Ghiaty, Ashraf H. Bayoumi, Hany E. A. Ahmed, Mona S. El-Zoghbi, Khaled El-Adl, ***Hamada S. Abulkhair***, *New Journal of Chemistry*, 2021, https://doi.org/10.1039/D1NJ00710F.
21. β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization, Mohammed I. A. Hamed, Khaled M. Darwish, Raya Soltane, Amani Chrouda, Ahmed Mostafa, Noura M. Abo Shama, Sameh S. Elhady, ***Hamada S. Abulkhair***, Ahmed E. Khodir, Ayman Abo Elmaaty and Ahmed A. Al-karmalawy, *RSC Advances,* 2021,**11**, 35536-35558. https://doi.org/10.1039/D1RA04820A

22. Unravelling the antifungal and antiprotozoal activities and LC-MS/MS quantification of steroidal saponins isolated from *Panicum turgidum*, Ahmed A. Zaki, Mohamed M. Y. Kaddah, ***Hamada S. Abulkhair*** and Ahmed Ashour, *RSC Advances,* 2022,**12**, 2980-2991. https://doi.org/10.1039/D1RA08532H
23. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization, Ayman Abo Elmaaty, Mohammed I. A. Hamed, Muhammad I. Ismail, Eslam B. Elkaeed, ***Hamada S. Abulkhair***, Muhammad Khattab, and Ahmed A. Al-Karmalawy, *Molecules*, 2021, https://doi.org/10.3390/molecules26123772
24. *N*-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies, Khaled El-Adl, Mohamed-Kamal Ibrahim, Fathalla Khedr, ***Hamada S. Abulkhair***, Ibrahim H. Eissa, *Archiv der Pharmazie*, 2021, 2000219, https://onlinelibrary.wiley.com/doi/full/10.1002/ardp.202000219
25. The antimicrobial potential and pharmacokinetic profiles of novel quinoline-based scaffolds: synthesis and in silico mechanistic studies as dual DNA gyrase and DHFR inhibitors, Mohamed H. El-Shershaby, Kamal M. El-Gamal, Ashraf H. Bayoumi, Khaled El-Adl, Mohamed Alswah, Hany E. A. Ahmed, Ahmed A. Al-Karmalamy, ***Hamada S. Abulkhair***, *New Journal of Chemistry*, 2021, https://10.1039/D1NJ02838C
26. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation, Khaled El-Adl, Helmy M. Sakr, Reda G. Yousef, Ahmed B. M. Mehany, Ahmed M. Metwaly, Mostafa A. Elhendawy, Mohamed M. Radwan, Mahmoud A.E lSohly, ***Hamada S. Abulkhair***, Ibrahim H.Eissa, *Bioorganic Chemistry*, 2021, 105105, https://doi.org/10.1016/j.bioorg.2020.105105
27. Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies, Amal Mahmoud, Ahmed Mostaf, Ahmed A. Al-Karmalawy, Ahmad Zidand, ***Hamada S. Abulkhair***, Sara H. Mahmoud, Mahmoud Shehata, Mahmoud M. Elhefnawi, Mohamed A. Ali, *Heliyon,* 2021, https://doi.org/10.1016/j.heliyon.2021.e07962
28. Pharmacophore-linked pyrazolo[3,4-d]pyrimidines as EGFR-TK inhibitors: Synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies, Ahmed A. Gaber, Ahmed M. El-Morsy, Farag F. Sherbiny, Ashraf H.

Bayoumi, Kamal M. El-Gamal, Khaled El-Adl, Ahmed A. Al-Karmalawy, Rogy R. Ezz Eldin, Marwa A. Saleh, ***Hamada S. Abulkhair***, *Archiv der Pharmazie*, 2021, 2000219, https://onlinelibrary.wiley.com/doi/full/10.1002/ardp.202100258

29. Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations, Fathalla Khedr, Mohamed-Kamal Ibrahim, Ibrahim H. Eissa, ***Hamada S. Abulkhair***, Khaled El-Adl, *Archiv der Pharmazie*, 2021, 2000201, https://onlinelibrary.wiley.com/doi/full/10.1002/ardp.202100201

30. New quinoxaline-2(1H)-ones as potential VEGFR-2 inhibitors: design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations, Reda G. Yousef, Helmy M. Sakr, Ibrahim H. Eissa, Ahmed B. M. Mehany, Ahmed M. Metwaly, Mostafa A. Elhendawy, Mohamed M. Radwan, Mahmoud A.E lSohly, ***Hamada S. Abulkhair***, Khaled El-Adl, *New Journal of Chemistry*, 2021, https://doi.org/10.1039/D1NJ02509K

31. Design, synthesis, docking and anticancer evaluations of phthalazines as VEGFR-2 inhibitors, Khaled El-Adl, Mohamed-Kamal Ibrahim, Fathalla Khedr, ***Hamada S. Abulkhair***, Ibrahim H. Eissa, *Archiv der Pharmazie*, 2021, 2000278, https://onlinelibrary.wiley.com/doi/full/10.1002/ardp.202100 278

32. *In vivo*-and *in silico*-driven identification of novel synthetic quinoxalines as anticonvulsants and AMPA inhibitors, ***Hamada S. Abulkhair***, Salwa Elmeligie, Adel Ghiaty, Ahmed El-Morsy, Ashraf H. Bayoumi, Hany E. A. Ahmed, Khaled El-Adl, Mohamed F. Zayed, Memy H. Hassan, Eman N. Akl, Mona S. El-Zoghbi, *Archiv der Pharmazie*, 2021, 2000491, https://onlinelibrary.wiley.com/doi/full/10.1002/ardp.202000449

33. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2, 4-dione derivatives as VEGFR-2 inhibitors, Khaled El-Adl, Helmy Sakr, Sanadelaslam S. El-Hddad, Abdel-Ghany A. El-Helby, Mohamed Nasser, ***Hamada S. Abulkhair***, *Archiv der Pharmazie*, 2021, 2000491, https://onlinelibrary.wiley.com/doi/full/10.1002/ardp.202000491

34. Design, synthesis, docking, anticancer and *in silico* pharmacokinetic studies of novel 5-([4-chloro/2,4-dichloro]benzylidene)thiazolidine-2,4-dione derived VEGFR-2 inhibitors, Khaled El-Adl, Mohamed-K. Ibrahim, Fathalla Khedr, ***Hamada S. Abulkhair***, Ibrahim H. Eissa, *Archiv der Pharmazie*, 2020, 2000279, https://doi.org/10.1002/ardp.202000279

35. Synthesis, antimicrobial evaluation, DNA gyrase inhibition, and *in silico* pharmacokinetic studies of novel quinoline derivatives, Mohamed H. El-Shershaby, Kamal M. El-Gamal, Ashraf H. Bayoumi, Khaled El-Adl, Hany E. A. Ahmed, ***Hamada S. Abulkhair***, *Archiv der Pharmazie*, 2020, 2000277, https://doi.org/10.1002/ardp.202000277

36. Novel 1,2,4-triazole derivatives: Design, synthesis, anticancer evaluation, molecular docking, and pharmacokinetic profiling studies, Abdallah Turky, Farag F. Sherbiny, Ashraf H. Bayoumi, Hany E. A. Ahmed, Khaled El-Adl, ***Hamada S. Abulkhair***, *Archiv der Pharmazie*, 2020, 2000170, https://doi.org/10.1002/ardp.202000170

37. Unravelling the anticancer potency of 1,2,4-triazole-*N*-arylamide hybrids through inhibition of STAT3: synthesis and in silico mechanistic studies, Abdallah Turky, Ashraf H. Bayoumi, Farag F. Sherbiny, Khaled El-Adl, ***Hamada S. Abulkhair***, *Molecular Diversity*, 2020, 10131, https://doi.org/10.1007/s11030-020-10131-0

38. Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: Design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies, ***Hamada S. Abulkhair***, Abdallah Turky, Adel Ghiaty, Hany E. A. Ahmed, Ashraf H. Bayoumi, *Bioorganic Chemistry*, 2020, 103899, https://doi.org/10.1016/j.bioorg.2020.103899.

39. Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: Apoptosisinductive and PCAF-inhibitory effects, Abdallah Turky, Ashraf H. Bayoumi, Adel Ghiaty, Adel S. Azab, Alaa A.-M. Abdel-Aziz, ***Hamada S. Abulkhair***, *Bioorganic Chemistry*, 2020, 104019, https://doi.org/10.1016/j.bioorg.2020.104019

40. Triazolophthalazine Incorporating Piperazine Derivatives: Synthesis and In Vitro Anticancer Evaluation Study, Abdallah Turky, Ashraf H. Bayoumi, Adel Ghiaty, ***Hamada S. Abulkhair***, *Az. J. Pharm Sci.* 2020, 61, 104-116. DOI: 10.21608/AJPS.2020.86020

41. The rational design, synthesis, and antimicrobial investigation of 2-Amino-4-Methylthiazole analogues inhibitors of GlcN-6-P synthase, Abdelsattar M. Omarab, SalehIhmaid, EL-Sayed E. Habib, Sultan S. Althagfan, Sahar Ahmed, ***Hamada S. Abulkhair***, Hany E. A. Ahmed, *Bioorganic Chemistry*, 2020, 99, 103781, https://doi.org/10.1016/j.bioorg.2020.103781

42. Design, synthesis, and molecular docking studies of new [1,2,4]triazolo[4,3-*a*]quinoxaline derivatives as potential A2B receptor antagonists, Hany G. Ezzat, Ashraf

H. Bayoumi, Farag F. Sherbiny, Ahmed M. El-Morsy, Adel Ghiaty, Mohamed Alswah & ***Hamada S. Abulkhair***, *Molecular Diversity* (2020). https://doi.org/10.1007/s11030-020-10070-w

43. Synthesis and antibacterial evaluation of a novel library of 2-(thiazol-5-yl)-1,3,4-oxadiazole derivatives against methicillin-resistant *Staphylococcus aureus* (MRSA), Mohamed H. Hannoun, Mohamed Hagras, Ahmed Kotb, Abdul-Aziz M. El-Attar, ***Hamada S. Abulkhair***, *Bioorganic Chemistry*, 2020, 94, 103364, https://doi.org/10.1016/j.bioorg.2019.103364

44. Design and synthesis of new heterocyclic compounds to overcome microbial resistance, *Al-Azhar Journal of Pharmaceutical Sciences*, 2019, 60 (2), 14-25, https://dx.doi.org/10.21608/ajps.2019.70231

45. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors, Abdel-Ghany A. El-Helby, Helmy Sakr, Ibrahim H. Eissa, ***Hamada S. Abulkhair***, Ahmed A. Al-Karmalawy, Khaled El-Adl, *Archiv der Pharmazie*, 2019, 352(10). https://doi.org/10.1002/ardp.201900113

46. Design, synthesis, in silico ADMET profile and GABA-A docking of novel phthalazines as potent anticonvulsants, Abdel-Ghany A. El-Helby, Rezk R. A. Ayyad Mohamed F. Zayed, ***Hamada S. Abulkhair***, Hazem Elkady, Khaled El-Adl, *Archiv der Pharmazie*, 2019, 352(5). https://doi.org/10.1002/ardp.201800387

47. Arylthiazole antibiotics targeting intracellular methicillin-resistant Staphylococcus aureus (MRSA) that interfere with bacterial cell wall synthesis, Islam Eid, Mohamed M. Elsebaei, Haroon Mohammad, Mohamed Hagras, Christine E. Peters, Youssef A. Hegazy, Bruce Cooper, Joe Pogliano, Kit Pogliano, ***Hamada S. Abulkhair***, Mohamed N. Seleem, Abdelrahman S. Mayhoub, *European Journal of Medicinal Chemistry*, 2017, 139, 665-673. https://doi.org/10.1016/j.ejmech.2017.08.039

48. Rational design, synthesis, pharmacophore modeling, and docking studies for identification of novel potent DNA-PK inhibitors, Saleh Ihmaid, Hany E. A. Ahmed, Adeeb Al-Sheikh Ali, Yousery E. Sherif, Hamadeh M. Tarazi, Sayed M. Riyad, Mohamed F. Zayed, ***Hamada S. Abulkhair***, Heba S. Rateb, *Bioorganic Chemistry,* 2017, 72, 234-247. https://doi.org/10.1016/j.bioorg.2017.04.014

49. Synthesis, characterization and *in vitro* antitumor evaluation of new pyrazolo[3,4-*d*]pyrimidine derivatives, Ahmed M. El-Morsy, Mohamed S. El-Sayed, ***Hamada S. Abulkhair***, *Open Journal of Medicinal Chemistry,* 7, 1-17, 2017. https://doi.org/10.4236/ojmc.2017.71001

50. Synthesis, Biological Evaluation and Binding Studies of New Flavone Derivatives as Adenosine A2B Receptor Antagonists, Farag F. Sherbiny, ***Hamada S. Abulkhair***, Adel Saad, Helmy Sakr, Ahmed Mustafa, *Al-Azhar Journal of Pharmaceutical Sciences*, 2016, 53(1), 73-89. https://dx.doi.org/10.21608/ajps.2016.6894

51. Molecular Docking, Synthesis and Biological Evaluation of Some Novel 2-Substituted-3-allyl-4(3*H*)-quinazolinone Derivatives as Anticonvulsant Agents, ***Hamada S. Abulkhair***, Kamal M El-Gamal, Khaled El-Adl and Mohamed F Fadl, *Medicinal Chemistry (Los Angeles),* 2016, 6(9), 593-603.

52. Synthesis, characterization and antimicrobial evaluation of some novel quinoline derivatives bearing different heterocyclic moieties, Kamal M. El-Gamal, Mohamed S. Hagrs, ***Hamada S. Abulkhair***, *Bulletin of Faculty of Pharmacy, Cairo University*, 2016, 54(2), 263–273. https://doi.org/10.1016/j.bfopcu.2016.08.002

53. Synthesis and preliminary antimicrobial evaluation of some new 6-methoxyquinoline-3-carbonitrile derivatives, Mohamed Hagrs, Ashraf H. Bayoumi, Kamal M. El-Gamal, Abdelrahman S. Mayhoub, ***Hamada S. Abulkhair***, *Beni-suef University Journal of Basic and Applied Sciences*, 4, 2015, 338–345. https://doi.org/10.1016/j.bjbas.2015.09.001

54. Synthesis and Evaluation of Some New (1,2,4) Triazolo(4,3-a)Quinoxalin-4(5H)-one Derivatives as AMPA Receptor Antagonists, ***Hamada S. Abulkhair***, Salwa Elmeligie, Ashraf Bayoumi, Adel Ghiaty, Ahmed El-Morsy, and Memy H. Hassan, *Journal of Heterocyclic Chemistry*, 50, 2013, 1202-1208. https://doi.org/10.1002/jhet.714

55. Synthesis and evaluation of some new 1,2,4-triazolo(4,3-a(quinoxalin-4-5H-one derivatives as AMPA receptor antagonists, Ashraf Bayoumi, Adel Ghiaty, Ahmed El-Morsy, ***Hamada S. Abulkhair***, Memy H. Hassan, Salwa Elmeligie, *Bulletin of Faculty of Pharmacy, Cairo University*, 50, 2012, 141–146. https://doi.org/10.1016/j.bfopcu.2012.05.002

Ad Hoc Reviewer

- Bioorganic Chemistry, Elsevier Publishing Company
- Journal of Advanced Research, Elsevier Publishing Company
- Journal of Heterocyclic Chemistry, John Wiley & Sons, Inc.
- Medicinal Chemistry Research, Springer.
- Frontiers in oncology.
- Future Medicinal Chemistry, Future Science Group
- ACS Omega, ACS

- Journal of Medicinal Chemistry, ACS
- Current Organic Chemistry, Bentham Science.
- Pharmaceutical Research, Springer.
- SN Applied Sciences, Springer.
- Science Progress, SAGE Group
- European Journal of Organic Chemistry
- ChemistrySelect
- Chemistry & Biodiversity

References:

1. Prof. Dr. **Abdelrahman S. Mayhoub**, Professor of Pharmaceutical Organic Chemistry, at ZewailCity of Sciences and Technology. **amayhoub@zewailcity.edu.eg**
2. Prof. Dr. **Ashraf Hassan Bayoumi**, Professor and Head of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, former Head of Central Administration of Pharmaceutical Affairs. **ashraf.bayoumi@azhar.edu.eg**